Pfizer forecasts 2023 sales of COVID products below estimates

Pfizer forecasts 2023 sales of COVID products below estimates

(Reuters) – Pfizer Inc on Tuesday forecast 2023 sales of its COVID-19 products that fell short of Wall Street expectations, hit by lower demand in international markets and slower uptake of booster vaccines.

The U.S. drugmaker said it expects sales of $13.5 billion from the vaccine for 2023, below Refinitiv estimates of $14.39 billion, and projected $8 billion in sales of its antiviral pill, Paxlovid, short of $10.33 billion the Street expects.

(Reporting by Manas Mishra and Bhanvi Satija in Bengaluru; Editing by Sriraj Kalluvila)

Oil Price Fundamental Daily Forecast – Pressured Ahead of Several Central Bank Rate HikesXRP Bulls Face Sub-$0.38 on SEC v Ripple Silence and Fed FearETH Needs a BTC Return to $23,500 to Support a Run at $1,700USD/JPY Fundamental Daily Forecast – Rangebound as Fed Takes Center StageDOGE Eyes $0.100 on Twitter News While SHIB Lags on Shibarium SilenceNASDAQ, S&P 500, Dow Jones Analysis – Stocks Retreat Amid Profit-TakingLoadingLoadingLoading